GSS genetic signatures limited

Ann: Preliminary Final Report, page-6

  1. 69 Posts.
    lightbulb Created with Sketch. 5
    Management has done really well in what they could. But there is no hiding the disappointments that a) FDA approval is not yet forthcoming, and b) no customer in the US has signed up yet. Given the crowdedness of the market, I suspect that the US opportunity is probably lost. Had EUA been granted in May, it would have been a very different story. We could be looking at upward towards >50m revenue in 2021 and sound profitability to lay the financial foundation for further product development. I suspect the reason is in the disfunctional FDA during the chaotic months. But regardless the net result for us shareholders is that GSS wasn't lucky enough to break early into the US market.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
36.5¢
Change
-0.015(3.95%)
Mkt cap ! $82.90M
Open High Low Value Volume
37.0¢ 37.0¢ 36.5¢ $7.667K 20.72K

Buyers (Bids)

No. Vol. Price($)
5 16957 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
37.5¢ 4419 1
View Market Depth
Last trade - 13.27pm 10/07/2025 (20 minute delay) ?
GSS (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.